Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Haematologica|January 19, 2010
High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myelomaJochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, et al.
Nature|March 3, 2016
Positron annihilation signatures associated with the outburst of the microquasar V404 CygniThomas Siegert, Roland Diehl, Jochen Greiner, et al.
International Journal of Oncology|February 13, 2009
The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responsesAnita Schmitt, Thomas F E Barth, Eva Beyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17)Lars Bullinger, Richard F Schlenk, Marlies Götz, et al.
International Journal of Molecular Sciences|July 26, 2020
Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and ImmunotherapyLisa K Puntigam, Sandra S Jeske, Marlies Götz, et al.
International Journal of Cancer|September 9, 2014
T cell-based targeted immunotherapies for patients with multiple myelomaLei Wang, Nan Jin, Anita Schmitt, et al.
Neoplasia (New York, N.Y.)|September 3, 2009
RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer diseaseKilian M Gust, Matthias D Hofer, Sven R Perner, et al.
International Journal of Cancer|April 28, 2015
Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigensVanessa Schneider, Lu Zhang, Markus Rojewski, et al.
Scientific Reports|February 9, 2026
Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancerPatrick J Schuler, Franziska Oliveri, Lisa Puntigam, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Pageof 8